Branch Retinal Vein Occlusion

Evaluation and management of branch retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

Lucentis for Branch Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with branch retinal vein occlusion and macular edema. Without treatment about 30 percent of have visual improvement. With treatment about 60 percent of patients have improved vision. Long term follow-up show that at 4 years, about half of the patients with branch retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Branch Retinal Vein Occlusion

Eylea was approved for treatment of branch retinal vein occlusion in late 2014. It is administered as an intravitreal injection monthly initially and then the treatment interval can be extended.


Branch Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Branch Retinal Vein Occlusion

Retinal Vein Occlusion Market Set to Record Exponential Growth by 2026  PortNews24

Retinal vein occlusion is blockage of retinal vein due to blood clot. Retinal vein occlusion is the second most common cause of visual impairment globally.

RVO patients at risk for loss to follow-up after anti-VEGF treatment  Healio

Ocular Surgery News | Despite the proven benefits of anti-VEGF injections for patients with retinal vein occlusion, a retrospective review of billing codes showed ...

Retinal Vein Occlusion Market Poised to Expand at a Robust Pace by 2026  Market Reporter

Retinal vein occlusion is blockage of retinal vein due to blood clot. Retinal vein occlusion is the second most common cause of visual impairment globally.

Prevalence of resolved paracentral acute middle maculopathy lesions in fellow eyes of patients with unilateral retinal vein occlusion  MD Linx

In this case-control observational study, researchers examined the prevalence of resolved paracentral acute middle maculopathy (PAMM) lesions in fellow eyes ...

Sales Scenario of Global Retinal Vein Occlusion Therapeutics Market to Remain Positive Through 2015-2021  Spaceflight News

Sales Scenario of Global Retinal Vein Occlusion Therapeutics Market to Remain Positive Through 2015-2021 | The Premier Source of Space Exploration and ...

Interesting Sessions to Come at ASRS 2019  MD Magazine

Here's a primer for new data and discussions MD Mag will be covering this weekend in Chicago.

Retinal Vein Occlusion Market Size and Forecasts Research Report 2019  Industry Stats News

Retinal Vein Occlusion Market research now available at Brand Essence Research encompasses an exhaustive Study of this business space with regards to ...

Global Retinal Vein Occlusion Market – Premium Insight, Industry Trends, Market Sizing & Forecasts to 2023  Technology Market

Introduction. Retinal vein occlusion is a retinal vascular disease that mainly affects the older population and causes blindness. The condition is basically of two ...

Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?  Yahoo Finance

Regeneron Pharmaceuticals, Inc. REGN is scheduled to release second-quarter 2019 results on Jul 6, before the opening bell. In the last reported quarter, the ...

Retinal Vein Occlusion Therapeutics Market 2025 Analysis, Industry Top Manufactures, Market Size, Industry Growth  The Jеnnеr Nеws

Global “Retinal Vein Occlusion Therapeutics Market” provides complete attention on major industry drivers, opportunities, challenges, and their impact on market ...

Protective effects of ADM-RAMP2 system make it a new therapeutic target for retinal vein occlusion  Medical Xpress

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

Global Retinal Vein Occlusion Market 2019 Industry Size, Emerging Technologies, Future Demands, Opportunities, Regional Trends and Industry Growth by Forecast 2023  News In Bites

Global “Retinal Vein Occlusion Market” 2019 Research report provides information regarding market size, share, trends, growth, cost structure, key drivers and ...

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

Global Retinal Vein Occlusion Therapeutics Market to Witness Heightened Revenue Growth During the Forecast Period  MelodyReports

Retinal vein occlusion (RVO) is one of the major cause of visual loss among the geriatric population. RVO is the second common cause of blindness after ...

Retinal Vein Occlusion Market Opportunity, Growth, Share, Demand, Innovation, Top Companies – Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers  News Exterior

Retinal Vein Occlusion Market report offers a comprehensive valuation of the marketplace. It does so via in-depth comprehensions, grateful market growth by ...

Retinal Vein Occlusion Market Outlook 2019 Witnessing Enormous Growth with Recent Trends & Demand |Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers  Market Research Finance

Retinal Vein Occlusion Market Forecast to 2025. New study on Industrial Growth of Retinal Vein Occlusion Market 2019-2025: The global Retinal Vein Occlusion ...

Global Retinal Vein Occlusion Therapeutics Market 2019 – Sanofi Aventis, Valeant Pharmaceuticals, Allergan, … – Honest News 24  Honest News 24

Global Retinal Vein Occlusion Therapeutics Market research report covers the analysis about business overview, market size, share, trends, gross margin, ...

Intravitreal Diclofenac in the Treatment of Macular Edema Due to Branch Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE: To evaluate the effect of a single dose of intravitreal diclofenac on macular ...

Anti-VEGF Therapy for Retinal Vein Occlusions  Medscape

Is anti-VEGF therapy more effective than the standard of care for retinal vein occlusions? In this video blog, David M. Brown, MD, reflects on the recent BRAVO ...

Young scientist helps identify cause of widespread eye disease  Science Daily

Branch retinal vein occlusion -- blockage of the blood vessels that channel blood from the retina -- is a common eye disease. A type of blood clot in the eye, the ...

Anti-VEGF treatment of macular edema associated with retinal vein occl | OPTH  Dove Medical Press

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2) J ...

Global Retinal Vein Occlusion Market 2019 – Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers  Biz Trends 24

The Retinal Vein Occlusion Market report presents key information on the market status of the key players and is a precious source of direct and plan for ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Shares Sold by Hussman Strategic Advisors Inc.  Mayfield Recorder

Hussman Strategic Advisors Inc. trimmed its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 33.3% in the 2nd quarter, according to ...

BRVO: Bevacizumab and Ranibizumab Both Effective  Medscape

Patients with branch retinal vein occlusion (BRVO) who have been treated with either bevacizumab or ranibizumab experienced significant gain in visual acuity.

Retinal Vein Occlusion Associated With Stroke  Medscape

Retinal vein occlusion (RVO) is significantly associated with stroke development, according to a recent study. Although the investigators adjusted for potential ...

Retinal Vascular Occlusion (RVO) Market Overview 2019, Global Industry Size, Share, SWOT Analysis, Technology Advancement, Competitive landscape, Regional Forecast to 2023 |  Medgadget

Retinal Vascular Occlusion (RVO) Market Overview Retinal disease burden has continued to rise worldwide, more so among the geriatric population. Many of.

Eylea Market Share 2x more Than Lucentis in WMD and 3x more in DME/DR based on Medicare Claims Analysis  Dexur

Dexur's analysis of medicare claims shows that Eylea (Aflibercept) is being used twice as much as Lucentis (Ranibizumab) for Wet Age-related Macular ...

THERAPIX BIOSCI/S (NASDAQ:TRPX) vs. Regeneron Pharmaceuticals (NASDAQ:REGN) Head to Head Comparison  Mayfield Recorder

THERAPIX BIOSCI/S (NASDAQ:TRPX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better investment?

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

RELATE study: Increased ranibizumab, laser yield minimal benefits  Healio

BOSTON — An increased dose of ranibizumab offered no added benefit in eyes with retinal vein occlusion, according to a study presented here. Additionally ...

Ozurdex for retinal vein occlusion available in China  Healio

Ozurdex is now available in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion, Allergan announced in a press ...

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment  Bel Marra Health

Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each ...

Bayer files eye drug Eylea for new use in EU  PMLiVE

Bayer has filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion ...

NICE backs Bayer's Eylea as first-line BRVO treatment  PMLiVE

Bayer's Eylea (aflibercept) has been recommended for use on the NHS in England and Wales as a first-line treatment for adults with branch retinal vein ...

Retinal artery and vein thrombotic occlusion during pregnancy: markers | OPTH  Dove Medical Press

Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse pregnancy outcomes Will S Kurtz,1 Charles J ...

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion  Markets Insider

--An estimated 7.4 million people in China are living with this sight-threatening conditioni,ii,iii --. DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc ...

Allergan's eye implant recalled due to foreign substance  Korea Biomedical Review

Allergan is recalling Ozurdex Intravitreal Implant 700㎍ (ingredient: dexamethasone), a steroid eye implant for macular edema, after detecting a foreign ...

Should We WAVE Goodbye to Laser?  Medscape

This study helps answer a common clinical question as to whether peripheral laser to areas of retinal ischemia improves vision and reduces injection burden in ...

BB&T Corp Increases Holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Mayfield Recorder

BB&T Corp grew its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.6% in the 2nd quarter, according to the company in its most ...

Boston Advisors LLC Has $268,000 Stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Mayfield Recorder

Boston Advisors LLC lowered its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 92.6% during the second quarter, according to its most recent ...

Kindred Biosciences (NASDAQ:KIN) and Regeneron Pharmaceuticals (NASDAQ:REGN) Financial Review  Tech Know Bits

Regeneron Pharmaceuticals (NASDAQ:REGN) and Kindred Biosciences (NASDAQ:KIN) are both medical companies, but which is the better stock? We will ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Short Interest Update  Mayfield Recorder

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was the recipient of a significant increase in short interest in June. As of June 30th, there was short interest ...

Global Placenta Growth Factor Market 2019 Alteogen Inc., Chengdu Kanghong Pharmaceuticals Group Co Ltd  The Industry News Room

The report on the Global Placenta Growth Factor Market offers complete data on the Placenta Growth Factor market. Components, for example, main players, ...

Visual Prognosis of Branch Retinal Artery Occlusion  Medscape (subscription)

What is the relationship between initial visual acuity and visual prognosis in patients with branch retinal artery occlusion (BRAO)?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Sees Significant Increase in Short Interest  Mayfield Recorder

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was the recipient of a significant growth in short interest in the month of June. As of June 30th, there was ...

Regeneron (REGN) to Report Q1 Earnings: What's in Store?  Yahoo Finance

Regeneron Pharmaceuticals, Inc. REGN is scheduled to release first-quarter 2019 results on May 7, before the opening bell. In the last reported quarter, the ...

Double-Barreled Biologic for Diabetic Retinopathy Emerging  Medscape

Trial results for the first biologic to target both the VEGF and Ang-2 pathways designed for less frequent injections than current options will be presented at the ...

Aflibercept Injections Superior to Laser for Macular Edema  Medscape

Intravitreal injections of aflibercept were more effective than laser therapy for the treatment of macular edema secondary to branch retinal vein occlusion, ...

Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the effects of squalamine (OHR-102; Ohr Pharmaceuticals, ...

Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)  PR Newswire

DUBLIN, Oct. 30, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that it has received an Imported Drugs License (IDL) from the Chinese Food ...

Hartford Investment Management Co. Grows Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Mayfield Recorder

Hartford Investment Management Co. lifted its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.8% during the 2nd quarter, according to its most ...

FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy  PR Newswire

TARRYTOWN, N.Y., Sept. 13, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug ...

Outlook Therapeutics Submits IND Application for ONS-5010 to the FDA  GlobeNewswire

CRANBURY, N.J., March 01, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) announced today the submission of its ...

Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010  GlobeNewswire

Enrollment of U.S. patients in the ONS-5010-002 Phase 3 clinical trial expected to be initiated in calendar Q2 2019.

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses  MD Magazine

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

High systolic BP affects your retina and may lead to complete vision loss  Economic Times

Constant fluctuations in the systolic pressure can lead to many major eye complications.

Retinopathy of Prematurity Clinical Practice Guidelines (2019)  Medscape

2019 guidelines on screening of preterm infants for retinopathy of prematurity by the AAP.

ZEISS Launches First Dual-Speed Swept-Source OCT/OCTA at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting  PRNewswire

The ZEISS PLEX Elite 2.0 is a dual-speed Swept-Source Optical Coherence Tomographer that provides expanded visualization options on how diseases are...

Steroid Injections May Help Restore Vision In Some Patients With Blocked Eye Veins  Science Daily (press release)

Injecting the eye with the corticosteroid triamcinolone appears effective in improving the vision of some patients with retinal vein occlusion, an important cause of ...

Cornerstone Advisors Inc. Sells 51 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Slater Sentinel

Cornerstone Advisors Inc. reduced its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 6.1% during the second quarter, according to the ...

Monthly, PRN doses of ranibizumab similarly effective in RVO  Healio

TORONTO — As-needed and monthly ranibizumab dosing regimens yielded similar visual acuity gains in patients with retinal vein occlusion who reached a ...

Chesley Taft & Associates LLC Sells 2,537 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Mayfield Recorder

Chesley Taft & Associates LLC lowered its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 66.5% during the second quarter, ...

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting  The Center for Biosimilars

In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT ...

Safety, Tolerability Increases Post-Bevacizumab Injection in Intraocular Pressure  MD Magazine

New research has shown that increased IOP is tolerable to corneal endothelium, and safe for most patients' eyes despite immediate increases post-injection.

Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)  BioSpace

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive, top line results from the Phase II LADDER study ...

Bayer's Eylea cleared for wider use in Europe  PMLiVE

Bayer's eye disease therapy Eylea has been cleared for a new macular oedema indication in the EU, stepping up competition against rival therapy Lucentis from ...

Branch Retinal Artery Occlusion (BRAO): Causes, Symptoms, Diagnosis, and Treatment  Bel Marra Health

Branch retinal artery occlusion or BRAO is a vision-related disease-causing long-term vision problems. It is caused due to reduced or blocked blood flow.

Retinal Vein Occlusion Market to Grow at CAGR of 11.2% through 2023  World Analytics

Retinal Vein Occlusion Market Highlights. Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients ...

EU Panel Recommends Luxturna for Inherited Retinal Dystrophy  Medscape

The EMA's CHMP has recommended marketing authorization for voretigene neparvovec for inherited retinal dystrophy caused by RPE65 gene mutations in ...

Fast Action Can Save Sight if Retina Is Detached or Blocked  New York Times

Modern treatments can do wonders if they are begun before the damage to the eye is irreversible.

NIH Vision Researcher Among Seven to Receive Top Global Award  Medscape

T. Michael Redmond and six others were honored for developing gene therapy for the blinding disorder Leber congenital amaurosis. It is the only pharmacologic ...

Eye Testing May Aid Early Diagnosis of Creutzfeldt-Jakob Disease  Medscape

Eye examinations may aid clinicians in the diagnosis of sporadic Creutzfeldt-Jacob disease (sCJD), results of a small postmortem study show. In an evaluation ...

Vision Loss Reported After Cosmetic Facial Injections  Medscape

Dermal filler injections in the forehead led to vision loss, a rare but devastating event, in 3 patients.

Eye strokes (retinal artery occlusion): Symptoms, causes, and treatment  Bel Marra Health

Eye strokes can come one suddenly and result in partial or complete loss of vision. Learn about cause, risk factors and treatment options.

VIDEO: High-resolution OCT findings of macular disorders  Healio

At Retina 2016, Elias Reichel, MD, shares cases of high-resolution OCT findings of macular disorders from his practice.

Blue Light Damages Retinal Cells in Lab Study  Medscape

A cell-based experiment shows how blue light can damage retinal cells, but it's unclear whether the results translate to humans or if blue light exposure from ...

Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate  PRNewswire

PALO ALTO, Calif., Dec. 21, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel...

Kodiak Sciences Announces First Quarter 2019 Financial Results and Recent Business Highlights  PRNewswire

PALO ALTO, Calif., May 15, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel ...

New data comparing Lucentis efficacy and durability versus aflibercept  The Pharma Letter

Swiss pharma giant Novartis (NOVN: VX) today reported new data from a Phase IV head-to-head study (RIVAL) confirming Lucentis (ranibizumab) efficacy and ...

Ranibizumab Outperforms Aflibercept in Efficacy, Durability  MD Magazine

According to the interim results of the RIVAL trial, ranibizumab (Lucentis) showed an increase of 2.2 more letters compared to aflibercept.

FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy  PRNewswire

TARRYTOWN, N.Y., May 13, 2019 /PRNewswire/ -- EYLEA improves diabetic retinopathy and prevents worsening disease that can lead to blindness Diabetic...

Outlook Is The One To Watch After Latest Advancements For Wet-AMD Treatment  Seeking Alpha

Outlook Therapeutics obtains clearance from FDA to initiate a second phase 3 study using its drug ONS-5010 to treat patients with wet age-related macular ...

New Trending Report on Retinal Vein Occlusion Market with high CAGR in Coming Years with Focusing Key players like Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers, etc.  Market Industry News

Latest Survey on Retinal Vein Occlusion Market 2019. A new business intelligence report released by Acquire Market Research with the title “Global Retinal ...

New AI Approach to Optical Coherence Tomography Images  Medscape

CHICAGO — Artificial intelligence programs can be trained to read optical coherence tomography (OCT) images in the same way that humans learn, by looking ...

Machine learning model predicts functional outcomes in early-stage mental illness  Healio

Findings from a multimodal, multisite machine learning analysis revealed that prediction models determined 1-year social-functioning outcomes in up to 83% of ...

New Geographic Atrophy Treatment Shows Promise  Medscape

VANCOUVER, Canada — An experimental treatment with an intravitreal complement C3 inhibitor (APL-2, Apellis Pharmaceuticals) slowed geographic atrophy ...

RETINA-AI Releases Android Version of Fluid-Intelligence -- World's First Mobile Artificial Intelligence App for Eye Care Providers  PR Newswire

HOUSTON, Oct. 22, 2018 /PRNewswire/ -- RETINA-AI has released an Android version of its app Fluid-Intelligence, the world's first mobile artificial intelligence ...

Zeiss receives FDA approval for OCT angiography technology  BioOptics World

Zeiss Medical Technology (Dublin, CA) has received FDA clearance for its AngioPlex OCT angiography technology, which enables ophthalmologists to use ...

Ozurdex approved for treatment of macular edema  Monthly Prescribing Reference

Allergan's Ozurdex (dexamethasone intravitreal implant) has been approved by the FDA for the treatment of macular edema following branch retinal vein ...

Pros and Cons of Compounded Pharmaceuticals | Medpage Today  MedPage Today

This article was adapted from a debate that Julia Haller, MD, and Dante Pieramici, MD, presented at the Retina Subspecialty Day prior to the 2016 American ...

Ropivacaine: Less Pain, Hemorrhage Risk During Vitrectomy  Medscape

The best intraoperative peribulbar anesthetic during vitrectomy is ropivacaine (1%) compared with bupivacaine, lidocaine, and a solution of bupivacaine and ...

NICE gives Bayer's Elyea a provisional 'no' for first-line use  PMLiVE

The National Institute of Health and Care Excellence (NICE) is poised to hand Bayer's Eylea a limited recommendation for the treatment of branch retinal vein ...

IRIS Registry Finds New AMD, DME Population Data  MD Magazine

Studies based on data from the world's largest clinical specialty database corrected commonly-perceived trends in ophthalmology.

New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD)  Business Wire

Faricimab – the first bispecific antibody designed for the eye – dosed every four months demonstrated sustained vision outcomes compared to monthly ...

Regeneron Eylea Hits 24-Week Primary Endpoint in Study  Nasdaq

Regeneron Pharmaceuticals, Inc. REGN announced positive topline results from the phase III study evaluating Eylea (aflibercept) Injection in moderately severe ...

Stem Cell Therapy Shows Promise for Retinal Degeneration  Medscape

Retinal pigment epithelial cells derived from human embryonic stem cells can be safely transplanted into the eyes of patients with retinal degeneration, with ...

RETINA-AI Releases the First Artificial Intelligence Mobile App for Eye-Care Providers: Fluid Intelligence by RETINA-AI  PR Newswire

HOUSTON, July 17, 2018 /PRNewswire/ -- RETINA-AI has developed and released the first Artificial Intelligence mobile app for eye-care providers. This app ...

EU expands use of Novartis' eye drug Lucentis  PharmaTimes

The treatment scope of Novartis' Lucentis has been expanded in Europe to include patients with visual impairment due to choroidal neovascularization (CNV) ...

Two-year data confirm efficacy of EYLEA® (aflibercept solution for injection) Treat and Extend dosi  PharmiWeb.com

Significant visual acuity gains observed in the first year of treatment with aflibercept were largely maintained for 96 weeks· Up to 60% of patients had an injection ...

US FDA Accepts Allergan's New Drug Application for Bimatoprost Sustained-Release in Patients with Open-Angle Glaucoma or Ocular Hypertension  PRNewswire

DUBLIN, July 17, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, ...

» Load more